The Company is also studying P1101 in the single-arm phase 2B EXCEED-ET trial (ClinicalTrials.gov Identifier: NCT05482971) to evaluate the efficacy, safety, and tolerability of P1101 in adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback